| Oct 24 |
Down -64.19% in 4 Weeks, Here's Why Shattuck Labs (STTK) Looks Ripe for a Turnaround
|
| Oct 8 |
After Plunging -68.96% in 4 Weeks, Here's Why the Trend Might Reverse for Shattuck Labs (STTK)
|
| Oct 2 |
Top Midday Decliners
|
| Oct 2 |
Shattuck Labs stock craters following pipeline and job cuts
|
| Oct 2 |
Shattuck cut to Neutral at Citi on program exit
|
| Oct 2 |
STTK Discontinues Cancer Program, Plans Workforce Cut, Stock Falls
|
| Oct 2 |
Shattuck Labs Refocuses Strategy Amidst Restructuring and Cuts
|
| Oct 1 |
Shattuck Labs Shutters Cancer Program, Lays Off Around 40% Of Its Workforce, Reorganizes Pipeline
|
| Oct 1 |
Shattuck plunges after discontinuing lead candidate
|
| Oct 1 |
Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway
|
